Atossa Therapeutics price target lowered to $10 from $35 at Craig-Hallum

Craig-Hallum lowered the firm’s price target on Atossa Therapeutics (ATOS) to $10 from $35 and keeps a Buy rating on the shares. The firm cites Atossa’s decision to pause Z-endoxifen’s development in metastatic breast cancer to prioritize other breast cancer settings and DMD. Z-endoxifen’s other breast cancer studies remain ongoing including the I-SPY and EVANGELINE studies in neoadjuvant breast cancer, where data updates are expected later this year. The year-end 2025 cash balance of about $40M provides at least one year of runway, argues Craig-Hallum.